02.10.26 -- Trump's Big Pharma Deals Drive CDMO Investments

AI is shifting from experimentation to execution in drug development. This OPCU special edition explores where AI delivers value today—across discovery, CMC, and quality—and how CDMOs and sponsors can collaborate to reduce risk, improve quality, and accelerate timelines, with practical guidance on readiness, regulatory considerations, and sponsor expectations.

ISO 21973 establishes global best practices for transporting cell and gene therapies, ensuring quality, safety, and consistency across complex supply chains critical to patient outcomes.

Silencing lentiviral cargo genes boosts vector yield, enhances cell viability, and reduces impurities, enabling scalable, cost-effective manufacturing for complex gene therapies.

As cell and gene therapies continue to advance, a well-integrated analytical framework will be critical for accelerating development timelines and optimizing regulatory submissions.

In vivo CAR-T is not simply ex vivo without a manufacturing step. It is a different modality that relies on biological systems to regulate outcomes.

See how one family managed to get an investigational gene replacement therapy manufactured and approved by the FDA so their daughter could be dosed just 14 months from her diagnosis.

Choosing the CDMO best suited to manufacture your rare disease therapy can be challenging. Ideally, a CDMO will prioritize your goals while working to ensure quality and regulatory success.

Next-generation sequencing (NGS) accelerates therapy development by enabling rapid, cost-effective DNA/RNA analysis crucial for cell and gene therapies, process optimization, and impurity detection.

Addressing the complexities of viral vector manufacturing through strategic internalization, advanced technologies, and regulatory excellence is crucial for the future of gene therapies.

The need for manufacturing support that offers adaptable, scalable solutions has become more crucial than ever for the diagnostic space.

What does it take to bring an adenovirus-based therapy to the clinic – faster and without compromising quality? Find actionable insights to help improve efficiency and accelerate development timelines.

Built on deep expertise in viral vector design and manufacturing, explore a comprehensive set of tools to rapidly deliver advanced therapies and support the development of next-generation treatments.

iPSC generation is a complex process of reprogramming adult somatic cells into a pluripotent, embryonic stem cell-like stage.

Achieve high monoclonal antibody and complex bispecific titers routinely with an IND-approved cell line development platform that integrates genetic tools and data-driven models.

This two-sided labeling machine brings precision and versatility to your production line. This high-speed workhorse labels up to 200 products per minute, even those with challenging shapes.